Thyroxine sulfate T4 Sulfate|cas:77074-49-8|西域试剂

Thyroxine sulfate T4 Sulfate,99.84%

产品编号：Bellancom-101406| CAS NO：77074-49-8| 分子式：C₁₅H₁₁I₄NO₇S| 分子量：856.93

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101406	￥800.00	杭州北京（现货）
Bellancom-101406	￥1300.00	杭州北京（现货）
Bellancom-101406	￥3900.00	杭州北京（现货）
Bellancom-101406	￥6200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Thyroxine sulfate T4 Sulfate

产品介绍

Thyroxine sulfate是甲状腺激素代谢物。

生物活性

Thyroxine sulfate is a thyroid hormone metabolite.

体外研究

Thyroxine sulfate (T4S) is a normal component of human serum and amniotic fluid, and it is mostly derived from thyroxine peripherally and accumulates when type I 5-monodeiodinating activity is low in fetuses or inhibited by drugs, such as ipodate.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Significant amounts of thyroxine sulfate (T4S) in fetal sheep serum, meconium, bile, and amniotic and allantoic fluids are observed. T4S concentration in amniotic fluid from women at 18-19 weeks of gestation (25.5 ng/dL) is higher than that at 14-15 weeks of gestation (14.3 ng/dL). A significant rise in serum T4S is detected in hyperthyroid patients 1 day after ingestion of 1 g of ipodate. Thyroxine undergoes significant sulfation in rats, and biliary excretion of T4S is enhanced if its type I deiodination is inhibited. Serum T4S levels are clearly elevated compared with healthy references, and the decreased deiodination by liver D1 during critical illness appears to play a role in this increase in serum T4S levels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 140 mg/mL (163.37 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1670 mL	5.8348 mL	11.6696 mL
5 mM	0.2334 mL	1.1670 mL	2.3339 mL
10 mM	0.1167 mL	0.5835 mL	1.1670 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5.75 mg/mL (6.71 mM); Clear solution

此方案可获得 ≥ 5.75 mg/mL (6.71 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 57.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 5.75 mg/mL (6.71 mM); Suspended solution; Need ultrasonic

此方案可获得 5.75 mg/mL (6.71 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 57.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.58 mg/mL (3.01 mM); Clear solution

此方案可获得 ≥ 2.58 mg/mL (3.01 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明